Acrux Limited soars on positive quarterly sales numbers: Is there time to buy?

Sales grew on the prior quarter, suggesting this business may be great value at today's prices.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Testosterone-therapy manufacturer Acrux Limited (ASX: ACR) today posted quarterly results showing sales of its Axiron product were up more than 19% on the prior quarter to US$47.1 million. Acrux also earned a milestone payment of US$25 million in March 2014, as the worldwide net sales of Axiron in the 2013 calendar year exceeded US$100 million.

Acrux lost around two-thirds of its market value from January 2014 after the U.S. Food and Drug Administration (FDA) announced that it was looking into potential adverse health effects of testosterone therapies like those produced by Acrux. This news spooked investors who rushed for the exits fearing the downstream effects on the sales of Axiron could be catastrophic.

However, today's news that quarterly sales have increased over the quarter ending March 2014, suggests medical professionals and users are still comfortable that the health benefits of testosterone therapy for men outweigh the known risks. This is also the FDA's current position, although it is yet to release the results of its current investigation.

Acrux has been one of the ASX's most shorted stocks recently as speculators sought to profit from the negative news flow surrounding the business. However, today's price spike may in part be a result of short covering, an effect that occurs when short sellers rush to close positions in the belief a stock has bottomed. This effect was also seen recently when another heavily-shorted biotech, Starpharma Holdings Limited (ASX: SPL), announced it had won regulatory approval to market its scientifically-innovative condoms in Japan and Australia.

Acrux is not out of the woods yet, but today's news suggest the worst of the storm may have blown over with potential for clear blue skies ahead.

Shares were up 9% to $1.26 in early trade.

Motley Fool contributor Tom Richardson owns shares in Acrux Limited. You can find him on Twitter @tommyr345

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »